{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:45:50Z","timestamp":1793418350098,"version":"4.5.0"},"reference-count":37,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Embolic stroke of undetermined source (ESUS) was proposed in 2014 as a clinical category to subgroup non-lacunar cryptogenic ischemic strokes that appear embolic but lack an identifiable cause despite thorough investigation. The initial hypothesis was that anticoagulation might offer superior secondary prevention compared to antiplatelet therapy, prompting several large clinical trials. This review synthesizes current knowledge on ESUS. ESUS represents about 17% of ischemic strokes and often affects younger patients with fewer traditional risk factors. Although these patients lack major cardioembolic sources (e.g., atrial fibrillation) or significant arterial stenosis, many have covert embolic substrates. Major trials\u2014NAVIGATE ESUS, RE-SPECT ESUS, and the atrial cardiopathy-focused ARCADIA\u2014found no benefit of anticoagulants over aspirin, challenging the original ESUS framework. These results highlight the heterogeneity within ESUS and underscore the need for individualized diagnostic and therapeutic strategies.<\/jats:p>","DOI":"10.3390\/medicina61071252","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:36:58Z","timestamp":1752161818000},"page":"1252","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Embolic Stroke of Undetermined Source (ESUS): Exploring the Neurocardiological Axis and Its Clinical Implications"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8765-7426","authenticated-orcid":false,"given":"Gabriela Dumachita","family":"Sargu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Elena Doamna Obstetrics and Gynecology University Hospital, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7386-0859","authenticated-orcid":false,"given":"Roxana","family":"Covali","sequence":"additional","affiliation":[{"name":"Department of Radiology, Elena Doamna Obstetrics and Gynecology University Hospital, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Filip","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6524-145X","authenticated-orcid":false,"given":"Tudor","family":"Butureanu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Elena Doamna Obstetrics and Gynecology University Hospital, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Akad","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Elena Doamna Obstetrics and Gynecology University Hospital, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"P\u0103v\u0103leanu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Elena Doamna Obstetrics and Gynecology University Hospital, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-1751","authenticated-orcid":false,"given":"Andrei Ionu\u021b","family":"Cucu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Biological Sciences, University Stefan cel Mare of Suceava, 720229 Suceava, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2874-9227","authenticated-orcid":false,"given":"Amelian M\u0103d\u0103lin","family":"Bobu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sf. Spiridon Hospital, 700111 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Riscanu","sequence":"additional","affiliation":[{"name":"Department of Morphophunctional Sciences, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lacatusu","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Physics, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Irina Smihor","sequence":"additional","affiliation":[{"name":"Department of Neurology, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: The case for a new clinical construct","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jacc.2019.11.024","article-title":"Embolic Stroke of Undetermined Source: JACC Review Topic of the Week","volume":"75","author":"Ntaios","year":"2020","journal-title":"J. Am. Coll Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","article-title":"CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation","volume":"370","author":"Sanna","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.maturitas.2019.01.004","article-title":"Cryptogenic stroke\u2014How to make sense of a non-diagnostic entity","volume":"122","author":"Schulz","year":"2019","journal-title":"Maturitas"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wang, W., Tang, X., Liu, W., Jia, K., Zhao, X., and Yu, F. (2020). Clinical Features of Embolic Stroke of Undetermined Source. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00058"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mart\u00ed-F\u00e0bregas, J., Delgado-Mederos, R., Crespo, J., Pe\u00f1a, E., Mar\u00edn, R., Jim\u00e9nez-Xarri\u00e9, E., Fern\u00e1ndez-Arcos, A., P\u00e9rez-P\u00e9rez, J., Mart\u00ednez-Dome\u00f1o, A., and Camps-Renom, P. (2015). Circulating endothelial progenitor cells and the risk of vascular events after ischemic stroke. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124895"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/STROKEAHA.116.016414","article-title":"Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update","volume":"48","author":"Hart","year":"2017","journal-title":"Stroke"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/1747493016641967","article-title":"ESUS Global Registry Investigators. Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry","volume":"11","author":"Perera","year":"2016","journal-title":"Int. J. Stroke"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/STROKEAHA.119.025384","article-title":"Left Atrial Volume Index Is Associated With Cardioembolic Stroke and Atrial Fibrillation Detection After Embolic Stroke of Undetermined Source","volume":"50","author":"Jordan","year":"2019","journal-title":"Stroke"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/STROKEAHA.113.003720","article-title":"Evaluation of cryptogenic stroke with advanced diagnostic techniques","volume":"45","author":"Bang","year":"2014","journal-title":"Stroke"},{"key":"ref_13","first-page":"2805","article-title":"Anticoagulation in subclinical atrial fibrillation: To treat or not to treat?","volume":"74","author":"Kaul","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1474-4422(18)30319-3","article-title":"NAVIGATE ESUS Investigators. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: A prespecified subgroup analysis from the NAVIGATE ESUS trial","volume":"17","author":"Kasner","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jamaneurol.2020.1995","article-title":"Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial","volume":"77","author":"Veltkamp","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hou, Y., Elmashad, A., Staff, I., Alberts, M., and Nouh, A. (2022). Potential Embolic Sources Differ in Patients With Embolic Stroke of Undetermined Source According to Age: A 15-Year Study. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.860827"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/17474930211009847","article-title":"Partitioning risk factors for embolic stroke of undetermined source using exploratory factor analysis","volume":"17","author":"Perkins","year":"2022","journal-title":"Int. J. Stroke"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/STROKEAHA.117.020059","article-title":"Atrial Cardiopathy and the Risk of Ischemic Stroke in the CHS (Cardiovascular Health Study)","volume":"49","author":"Kamel","year":"2018","journal-title":"Stroke"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1056\/NEJMoa1311376","article-title":"EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke","volume":"370","author":"Gladstone","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"NAVIGATE ESUS Investigators. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source","volume":"378","author":"Hart","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"CLOSE Investigators. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke","volume":"377","author":"Mas","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","article-title":"RESPECT Investigators. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke","volume":"377","author":"Saver","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/STROKEAHA.120.032002","article-title":"Cancer and Embolic Stroke of Undetermined Source","volume":"52","author":"Navi","year":"2021","journal-title":"Stroke"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.01.027","article-title":"NAVIGATE ESUS Steering Committee and Investigators. Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial","volume":"27","author":"Kasner","year":"2018","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source","volume":"380","author":"Diener","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pirera, E., D\u2019Anna, L., Di Raimondo, D., and Tuttolomondo, A. (2024). Direct Oral Anticoagulants Versus Aspirin for Stroke Prevention After Embolic Stroke of Undetermined Source: An Updated Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226730"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJM199412013312202","article-title":"Atherosclerotic disease of the aortic arch and the risk of ischemic stroke","volume":"331","author":"Amarenco","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Fuentes, B., Guti\u00e9rrez-Z\u00fa\u00f1iga, R., and D\u00edez-Tejedor, E. (2020). It\u2019s Time to Say Goodbye to the ESUS Construct. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00653"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.123.067512","article-title":"Direct Oral Anticoagulants for Stroke Prevention in Patients with Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials","volume":"149","author":"McIntyre","year":"2024","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/23969873241247978","article-title":"European Stroke Organisation (ESO) Guidelines on the Diagnosis and Management of Patent Foramen Ovale (PFO) After Stroke","volume":"9","author":"Caso","year":"2024","journal-title":"Eur. Stroke J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4103\/singaporemedj.SMJ-2022-143","article-title":"Use of Wearable Technology in Cardiac Monitoring After Cryptogenic Stroke or Embolic Stroke of Undetermined Source: A Systematic Review","volume":"65","author":"Ho","year":"2024","journal-title":"Singapore Med. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2023.27188","article-title":"ARCADIA Investigators. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial","volume":"331","author":"Kamel","year":"2024","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1161\/CIRCULATIONAHA.121.055176","article-title":"RE-SPECT ESUS Steering Committee and Investigators. Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial","volume":"144","author":"Bahit","year":"2021","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/eurheartj\/ehae150","article-title":"Embolic strokes of undetermined source: A clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC","volume":"45","author":"Ntaios","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/STROKEAHA.118.024160","article-title":"Do the Results of RE-SPECT ESUS Call for a Revision of the Embolic Stroke of Undetermined Source Definition?","volume":"50","author":"Paciaroni","year":"2019","journal-title":"Stroke"},{"key":"ref_37","first-page":"EVIDoa2300235","article-title":"Apixaban versus Aspirin for Embolic Stroke of Undetermined Source","volume":"3","author":"Geisler","year":"2024","journal-title":"NEJM Evid."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1252\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:07:58Z","timestamp":1760033278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["medicina61071252"],"URL":"https:\/\/doi.org\/10.3390\/medicina61071252","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}